©IDOSR PUBLICATIONS International Digital Organization for Scientific Research

IDOSR JOURNAL OF SCIENTIFIC RESEARCH 11(2):90-95, 2026. ISSN: 2550-794X

https://doi.org/10.59298/IDOSRJSR/2026/11.2.9095 IDOSRJSR11106

Nanotechnology-Based Interventions for Obesity-Associated Insulin Resistance and Diabetes Progression

Mercy Latricia

Department of Pharmacognosy Kampala International University Uganda
Email: atricia.mercy@studwc.kiu.ac.ug

ABSTRACT

Obesity is a leading risk factor for the development of insulin resistance and type 2 diabetes (T2D), creating a global health crisis. Insulin resistance, characterized by the inability of cells to respond to insulin effectively, is at the core of both obesity and T2D pathophysiology. Traditional treatment strategies often fail to address the root causes of these conditions, focusing mainly on symptom management rather than the underlying molecular mechanisms. Nanotechnology-based interventions present a promising solution, offering the ability to precisely target molecular pathways that drive insulin resistance, regulate lipid metabolism, and modulate inflammatory responses. This review explores the application of nanotechnology in addressing obesity-associated insulin resistance and halting the progression of diabetes. We examine innovative nanocarrier systems, drug delivery technologies, and biomolecular modulation strategies that can directly target adipose tissue, muscle, liver, and pancreas, which are key organs involved in the regulation of glucose homeostasis. Additionally, we discuss the clinical potential, challenges, and future directions for the integration of nanotechnology into the management of obesity-related insulin resistance and diabetes.

Keywords: Nanotechnology, Insulin Resistance, Obesity, Type 2 Diabetes, Drug Delivery.

INTRODUCTION

Obesity and type 2 diabetes (T2D) are two of the most prevalent metabolic disorders worldwide, with obesity serving as a major risk factor for the development of insulin resistance, a hallmark of T2D[1–4]. Obesity, particularly the accumulation of visceral fat, induces a range of metabolic disturbances, including dysregulated adipokine secretion, chronic low-grade inflammation, and altered lipid metabolism. These disturbances impair insulin signaling in key tissues such as the liver, muscle, and adipose tissue, contributing to the development of insulin resistance[5–8].

Insulin resistance occurs when the body's cells become less responsive to insulin, the hormone responsible for regulating blood glucose levels. As a result, insulin production increases in an attempt to compensate for the reduced efficacy of insulin[9–12]. Over time, this leads to β-cell dysfunction in the pancreas, exacerbating hyperglycemia and advancing the progression of T2D.

Current therapeutic approaches, such as oral hypoglycemic agents, insulin therapy, and lifestyle interventions, primarily focus on managing blood sugar levels rather than targeting the underlying causes of insulin resistance[13]. Given the complex interplay of genetic, environmental, and metabolic factors driving obesity-related insulin resistance, there is a growing need for more effective, targeted therapies that can address the root causes of the condition[14].

Nanotechnology-based interventions present a transformative approach to treating insulin resistance and halting the progression of diabetes[15, 16]. By exploiting the unique properties of nanoparticles and nanomaterials, it is possible to develop highly targeted and efficient therapeutic strategies that can modulate insulin sensitivity, reduce inflammation, and improve metabolic function at the molecular level. This review explores the potential of nanotechnology to address obesity-associated insulin resistance and diabetes progression through innovative drug delivery systems, biomolecular modulation, and tissue-specific therapies.

Pathophysiology of Obesity-Associated Insulin Resistance and Diabetes Progression

Obesity is characterized by excessive fat accumulation, particularly in visceral adipose tissue (VAT), which is metabolically active and releases a variety of bioactive molecules known as adipokines[17–20]. In obese individuals, adipocytes undergo hypertrophy and dysfunction, leading to an altered adipokine profile that

includes an increase in pro-inflammatory cytokines such as TNF-α, IL-6, and resistin. These cytokines play a key role in the development of insulin resistance by disrupting insulin signaling pathways[21, 22].

The primary role of insulin is to facilitate the uptake of glucose by peripheral tissues such as muscle and adipose tissue[9, 23, 24]. In insulin resistance, this signaling process becomes impaired, leading to decreased glucose uptake, elevated blood glucose levels, and compensatory hyperinsulinemia. As a result, the pancreas produces more insulin to overcome the resistance, leading to β-cell exhaustion and eventual dysfunction.

In addition to inflammation, obesity also results in dyslipidemia, particularly elevated levels of circulating free fatty acids (FFAs), which contribute to insulin resistance. FFAs are stored in non-adipose tissues, including the liver and skeletal muscle, where they interfere with insulin signaling and glucose uptake[25–27]. In the liver, excessive lipid accumulation leads to non-alcoholic fatty liver disease (NAFLD), a condition that exacerbates insulin resistance and increases the risk of T2D.

The progression of insulin resistance to T2D involves further β-cell dysfunction, which ultimately leads to the inability of the pancreas to produce sufficient insulin to maintain normal blood glucose levels[28, 29]. The culmination of these processes results in hyperglycemia, a defining feature of T2D, and the onset of complications such as cardiovascular disease, neuropathy, and retinopathy.

Nanotechnology-Based Drug Delivery Systems for Modulating Insulin Sensitivity

One of the most promising applications of nanotechnology in treating obesity-related insulin resistance and diabetes is the development of drug delivery systems that can target specific tissues and organs involved in glucose metabolism[30]. Traditional drug delivery methods often fail to deliver therapeutic agents to the intended target sites in sufficient concentrations, resulting in suboptimal therapeutic outcomes. Nanoparticles, with their small size and large surface area, offer a solution by enabling precise delivery of drugs to specific tissues, such as adipose tissue, muscle, and pancreas[30].

Lipid-based nanoparticles, such as liposomes and solid lipid nanoparticles (SLNs), are commonly used for encapsulating hydrophobic drugs that are poorly soluble in water[15, 26, 31]. These nanoparticles can be functionalized with targeting ligands, such as antibodies, peptides, or small molecules, to enhance their specificity for particular cells involved in the insulin resistance pathway. For example, nanoparticles can be designed to target insulin-resistant adipocytes or pancreatic β-cells, ensuring that drugs are delivered precisely where they are needed[32, 33].

Polymeric nanoparticles also hold significant potential for targeted drug delivery. These nanoparticles can be engineered to release their cargo in response to specific environmental stimuli, such as changes in pH or temperature, or over an extended period[34–36]. This controlled release ensures that therapeutic agents are delivered at the right time and in the right amounts to their intended target, improving treatment efficacy[34]. By using nanotechnology to deliver insulin-sensitizing agents, such as metformin or thiazolidinediones (TZDs), directly to tissues such as the liver and skeletal muscle, nanoparticles can help restore normal insulin sensitivity and improve glucose metabolism. Additionally, these nanocarriers can be designed to simultaneously deliver multiple agents, offering a combination therapy that addresses inflammation, lipid metabolism, and insulin resistance in a single treatment.

Nanoparticles for Modulating Inflammation in Obesity and Diabetes

Chronic inflammation is a central feature of obesity-associated insulin resistance and T2D. Inflammatory cytokines, such as TNF-α, IL-6, and CRP, impair insulin signaling and promote insulin resistance in adipose tissue, muscle, and liver[9, 10, 24]. Nanotechnology offers a promising strategy to modulate this inflammatory response by delivering anti-inflammatory agents directly to inflamed tissues.

Smart nanoparticles can be engineered to encapsulate small molecule inhibitors or RNA-based therapies that target key inflammatory pathways[37]. For example, nanoparticles can carry cytokine inhibitors that block the action of TNF-α or IL-6, or agents that inhibit the NF-κB pathway, which is involved in the inflammatory response[37, 38]. By targeting these pathways specifically in adipose tissue or muscle, these nanoparticles can reduce systemic inflammation and improve insulin sensitivity. Moreover, nanoparticles can be designed to release their cargo in response to specific inflammatory markers, ensuring that anti-inflammatory drugs are delivered only when needed. This targeted approach minimizes systemic side effects and enhances the effectiveness of the therapy.

5. Nanotechnology for Regulating Lipid Metabolism and Adipogenesis

Dysregulated lipid metabolism is a central pathological feature underlying obesity-associated insulin resistance and the progression of type 2 diabetes (T2D)[39]. In healthy metabolic states, adipose tissue serves as the primary site for lipid storage, preventing ectopic lipid accumulation in insulin-sensitive organs such as the liver, skeletal muscle, and pancreas[39]. However, in obesity, excessive lipid influx and impaired adipocyte function lead to lipotoxicity, chronic inflammation, and impaired insulin signaling[40, 41]. Nanotechnology offers a powerful and innovative platform for selectively modulating lipid metabolic pathways and adipogenesis, thereby restoring metabolic homeostasis.

Nanoparticle-based delivery systems enable precise targeting of key enzymes and signaling pathways involved in lipogenesis, lipolysis, and fatty acid oxidation[34, 38]. Lipogenesis, the process of de novo fatty acid synthesis, is often upregulated in obesity, contributing to excessive triglyceride accumulation[42]. Nanocarriers can be engineered to deliver small-molecule inhibitors or nucleic acid–based therapeutics targeting critical lipogenic

regulators such as acetyl-CoA carboxylase (ACC), fatty acid synthase (FASN), and sterol regulatory element-binding proteins (SREBPs)[42]. By selectively suppressing these enzymes in adipose tissue or liver, nanoparticles can reduce lipid synthesis while minimizing systemic adverse effects associated with conventional pharmacological inhibition.

In parallel, nanotechnology facilitates the targeted delivery of agents that enhance fatty acid oxidation and mitochondrial function, promoting lipid utilization rather than storage[43]. Compounds that activate AMP-activated protein kinase (AMPK), peroxisome proliferator-activated receptor alpha (PPAR-α), or mitochondrial biogenesis pathways can be encapsulated within nanoparticles to improve bioavailability and tissue specificity. Enhanced fatty acid oxidation reduces ectopic lipid deposition in non-adipose tissues, alleviating lipotoxic stress and improving insulin sensitivity in peripheral tissues[43].

Beyond lipid turnover, nanotechnology plays a critical role in regulating adipogenesis, the differentiation of pre-adipocytes into mature adipocytes. While adipogenesis is essential for healthy adipose tissue expansion, excessive or dysregulated adipocyte differentiation contributes to adipose hypertrophy, inflammation, and insulin resistance[44]. Nanocarriers can deliver small-molecule inhibitors, peptides, or RNA-based therapeutics such as siRNA or miRNA mimics to modulate the expression of adipogenic transcription factors including peroxisome proliferator-activated receptor gamma (PPAR-γ) and CCAAT/enhancer-binding protein alpha (C/EBP-α). Controlled inhibition of these transcriptional programs can limit pathological adipocyte expansion while preserving essential adipose tissue functions[44].

Importantly, nanotechnology enables cell- and depot-specific targeting, allowing differential modulation of white, brown, and beige adipose tissues[45, 46]. Targeting strategies that promote browning of white adipose tissue or enhance thermogenic activity in brown adipose tissue may further increase energy expenditure and lipid utilization. Surface-functionalized nanoparticles, responsive to adipose-specific markers or metabolic cues, provide an avenue for achieving such precision[44].

Collectively, nanotechnology-driven regulation of lipid metabolism and adipogenesis represents a multifaceted therapeutic strategy capable of addressing the metabolic complexity of obesity and diabetes. By enabling targeted, controlled, and combinatorial interventions, nanoparticle-based systems hold substantial promise for restoring lipid balance and improving insulin responsiveness.

Clinical Prospects and Challenges in Nanotechnology-Based Interventions

Nanotechnology-based interventions have demonstrated remarkable potential in preclinical models of obesity, insulin resistance, and type 2 diabetes. By enabling targeted delivery, improved pharmacokinetics, and reduced off-target toxicity, nanomedicine offers a paradigm shift in the management of metabolic disorders. However, despite these advances, several critical challenges must be addressed to facilitate successful clinical translation.

A primary concern is the safety and biocompatibility of nanoparticles. Due to their nanoscale dimensions and high surface area, nanoparticles can interact extensively with biological systems, leading to unintended biodistribution and accumulation in organs such as the liver, spleen, kidneys, and lungs[47, 48]. Persistent accumulation may induce oxidative stress, inflammation, or immune activation, particularly with long-term or repeated dosing, an important consideration for chronic diseases such as obesity and diabetes. Comprehensive toxicological evaluations, including long-term exposure studies, immunogenicity assessments, and biodegradation analyses, are essential to establish acceptable safety profiles[48].

Another major challenge lies in the complex pathophysiology of obesity and T2D, which involves interconnected pathways regulating lipid metabolism, glucose homeostasis, inflammation, and hormonal signaling. Effective nanomedicine strategies must therefore be multifunctional, capable of simultaneously targeting multiple disease-driving mechanisms[49]. Designing such multifunctional nanoparticles, incorporating targeting ligands, therapeutic payloads, and controlled-release properties, requires advanced nanomaterial engineering and precise control over physicochemical characteristics such as particle size, surface charge, and stability[49].

Manufacturing scalability and reproducibility further complicate clinical translation. Many nanocarrier systems that perform well at the laboratory scale face challenges in large-scale production, including batch-to-batch variability and difficulties in maintaining consistent quality[50]. Achieving Good Manufacturing Practice (GMP)-compliant production while preserving functional integrity remains a key hurdle[50].

Additionally, the regulatory landscape for nanomedicines is still evolving. Regulatory agencies, including the U.S. Food and Drug Administration and the European Medicines Agency, are actively developing frameworks to assess the safety, efficacy, and quality of nanotechnology-based therapeutics[51]. However, the lack of standardized regulatory guidelines can delay approval processes and increase development costs. Detailed characterization of nanomaterials, including their physicochemical properties, pharmacokinetics, and biodistribution, is often required beyond conventional drug evaluation standards[51].

Despite these challenges, the clinical prospects of nanotechnology-based interventions remain highly promising. Continued advances in biodegradable materials, precision targeting, and personalized nanomedicine, combined with collaborative efforts between researchers, clinicians, and regulatory bodies, are likely to accelerate the integration of nanotechnology into routine clinical management of obesity and diabetes.

CONCLUSION

Nanotechnology-based interventions represent a powerful and innovative approach to tackling obesity-associated insulin resistance and the progression of diabetes, conditions driven by complex and interconnected metabolic disturbances. By enabling targeted delivery of antidiabetic agents, anti-inflammatory compounds, and gene-based therapeutics, nanoplatforms enhance therapeutic efficacy while minimizing off-target effects and systemic toxicity. In parallel, nanoscale biosensors and imaging tools provide opportunities for early detection, continuous monitoring, and personalized management of metabolic dysfunction. Importantly, nanotechnology facilitates precise modulation of key molecular pathways involved in adipose tissue inflammation, lipid dysregulation, oxidative stress, and pancreatic β-cell dysfunction, which are central to disease progression. Despite encouraging preclinical and early clinical outcomes, challenges related to long-term biocompatibility, large-scale manufacturing, regulatory approval, and equitable accessibility remain. Addressing these barriers through interdisciplinary collaboration will be essential for clinical translation. Overall, nanotechnology offers a promising framework for precision-driven prevention and treatment strategies, with the potential to significantly alter the clinical landscape of obesity-associated diabetes.

REFERENCES

1. Allocca, S., Monda, A., Messina, A., Casillo, M., Sapuppo, W., Monda, V., Polito, R., Maio, G.D., Monda, M., Marra, M.L.: Endocrine and Metabolic Mechanisms Linking Obesity to Type 2 Diabetes: Implications for Targeted Therapy. Healthcare. 13, (2025). https://doi.org/10.3390/healthcare13121437
2. Oh, K.-J., Lee, D.S., Kim, W.K., Han, B.S., Lee, S.C., Bae, K.-H.: Metabolic Adaptation in Obesity and Type II Diabetes: Myokines, Adipokines and Hepatokines. Int. J. Mol. Sci. 18, (2016). https://doi.org/10.3390/ijms18010008
3. Pillon, N.J., Loos, R.J.F., Marshall, S.M., Zierath, J.R.: Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care. Cell. 184, 1530–1544 (2021). https://doi.org/10.1016/j.cell.2021.02.012
4. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. Discov. Public Health. 22, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
5. Mohaghegh, N., Balajam, N.Z., Hosseinpour, B., Buttles, C., Huang, Q., Huang, Y., Ahari, A., Farhadi, N., Davani, S., Khosravi, S., Mirmashhouri, B., Kouchehbaghi, N.H., Sampath, R., Akbari, M., Jucaud, V., Kang, H., Khademhosseini, A., Pearson, R.M., Najafabadi, A.H.: Immunoengineering strategies using nanoparticles for obesity treatment. Nano Res. 18, 94907707 (2025). https://doi.org/10.26599/NR.2025.94907707
6. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
7. Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Targeting CD44-Hyaluronic Acid Signalling in Obesity Treatment: Insights from Small Molecules and Nanobioconjugates. Nutr. Metab. Insights. 19, 11786388251408961 (2026). https://doi.org/10.1177/11786388251408961
8. Ezichi Favour, O., Chinwendu Angela, O., Tiffany Ezinne, G., Chioma Juliet, A., Sandra C, O., Simeon, B., Chidera Godson, C., Uzochukwu Eric, O., Chibuzo Collette, A., Justina Onyinyechi, O., Henry Nnaemeka, O.: Current Insights on the Effects of Medicinal Plants in the Management of Obesity and Infectious Diseases: An Update from 2020. Asp. Mol. Med. 100075 (2025). https://doi.org/10.1016/j.amolm.2025.100075
9. Wondmkun, Y.T.: Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications. Diabetes Metab. Syndr. Obes. Targets Ther. 13, 3611–3616 (2020). https://doi.org/10.2147/DMSO.S275898
10. Snel, M., Jonker, J.T., Schoones, J., Lamb, H., de Roos, A., Pijl, H., Smit, J.W.A., Meinders, A.E., Jazet, I.M.: Ectopic Fat and Insulin Resistance: Pathophysiology and Effect of Diet and Lifestyle Interventions. Int. J. Endocrinol. 2012, 983814 (2012). https://doi.org/10.1155/2012/983814
11. Suren Garg, S., Kushwaha, K., Dubey, R., Gupta, J.: Association between obesity, inflammation and insulin resistance: Insights into signaling pathways and therapeutic interventions. Diabetes Res. Clin. Pract. 200, 110691 (2023). https://doi.org/10.1016/j.diabres.2023.110691
12. Orji, U.O., Ibiam ,Udu Ama, Awoke ,Joshua Nonso, Atoki ,Ayomide Victor, Eze ,Ejike Daniel, Obasi ,Otuomasiri Divine, Ogbu ,Celestine, Ezeani ,Nkiru Nwamaka, Alum ,Esther Ugo, Aloke ,Chinyere, Uti ,Daniel Etim, and Aja, P.M.: Ethanolic extract of Cnidoscolus aconitifolius leaves alleviates insulin resistance by modulating oxidative stress and inflammation in albino rats exposed to heavy metal mixture. Nat. Prod. Res. 0, 1–14. https://doi.org/10.1080/14786419.2025.2478654
13. Gieroba, B., Kryska, A., Sroka-Bartnicka, A.: Type 2 diabetes mellitus – conventional therapies and future perspectives in innovative treatment. Biochem. Biophys. Rep. 42, 102037 (2025). https://doi.org/10.1016/j.bbrep.2025.102037
14. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obes. Med. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622

15. Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
16. Srivastava, A., Ahmad, A., Siddiqui, S., Islam, A.: Innovations in targeted drug delivery: From nanotechnology to clinical applications. Nanotechnol. 9, 100336 (2026). https://doi.org/10.1016/j.nxnano.2025.100336
17. Alexaki, V.I.: Adipose tissue-derived mediators of systemic inflammation and metabolic control. Curr. Opin. Endocr. Metab. Res. 37, 100560 (2024). https://doi.org/10.1016/j.coemr.2024.100560
18. Auger, C., Kajimura, S.: Adipose Tissue Remodeling in Pathophysiology. Annu. Rev. Pathol. Mech. Dis. 18, 71–93 (2023). https://doi.org/10.1146/annurev-pathol-042220-023633
19. Bartelt, A., Widenmaier, S.B., Schlein, C., Johann, K., Goncalves, R.L.S., Eguchi, K., Fischer, A.W., Parlakgül, G., Snyder, N.A., Nguyen, T.B., Bruns, O.T., Franke, D., Bawendi, M.G., Lynes, M.D., Leiria, L.O., Tseng, Y.-H., Inouye, K.E., Arruda, A.P., Hotamisligil, G.S.: Brown adipose tissue thermogenic adaptation requires Nrf1-mediated proteasomal activity. Nat. Med. 24, 292–303 (2018). https://doi.org/10.1038/nm.4481
20. Jayarathne, S., Koboziev, I., Park, O.-H., Oldewage-Theron, W., Shen, C.-L., Moustaid-Moussa, N.: Anti-Inflammatory and Anti-Obesity Properties of Food Bioactive Components: Effects on Adipose Tissue. Prev. Nutr. Food Sci. 22, 251–262 (2017). https://doi.org/10.3746/pnf.2017.22.4.251
21. Venkatesan, K., Paulsamy, P., Alqahtani, S., Asiri, Y.I., Alqahtani, T., Alqahtani, A., Sivadasan, D., Ahmed, R., Elfadil, H., Asseri, K.A., Qureshi, A.A., Velraj, M., Krishnaraju, K.: An update on the role of inflammation in insulin resistance and islet β cell failure- A crosstalk between immune cells, adipose tissue, cytokines, and oxidative stress. Lett. Drug Des. Discov. 22, 100023 (2025). https://doi.org/10.1016/j.lddd.2025.100023
22. Bhol, N.K., Bhanjadeo, M.M., Singh, A.K., Dash, U.C., Ojha, R.R., Majhi, S., Duttaroy, A.K., Jena, A.B.: The interplay between cytokines, inflammation, and antioxidants: mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds. Biomed. Pharmacother. 178, 117177 (2024). https://doi.org/10.1016/j.biopha.2024.117177
23. Bansal, S.K., Bansal, M.B.: Pathogenesis of MASLD and MASH – role of insulin resistance and lipotoxicity. Aliment. Pharmacol. Ther. 59, S10–S22 (2024). https://doi.org/10.1111/apt.17930
24. Rabiee, A., Hossain, M.A., Poojari, A.: Adipose Tissue Insulin Resistance: A Key Driver of Metabolic Syndrome Pathogenesis. Biomedicines. 13, 2376 (2025). https://doi.org/10.3390/biomedicines13102376
25. Bays, H.E., Kirkpatrick, C., Maki, K.C., Toth, P.P., Morgan, R.T., Tondt, J., Christensen, S.M., Dixon, D., Jacobson, T.A.: Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. Obes. Pillars. 10, 100108 (2024). https://doi.org/10.1016/j.obpill.2024.100108
26. Herdiana, Y., Levita, J., Jiranusornkul, S.: Chitosan-Based Nanoparticles Targeted Delivery System: In Treatment Approach for Dyslipidemia. Int. J. Nanomedicine. 20, 6611–6636 (2025). https://doi.org/10.2147/IJN.S517492
27. Roy, P.K., Islam, J., Lalhlenmawia, H.: Prospects of potential adipokines as therapeutic agents in obesity-linked atherogenic dyslipidemia and insulin resistance. Egypt. Heart J. 75, 24 (2023). https://doi.org/10.1186/s43044-023-00352-7
28. Dludla, P.V., Mabhida, S.E., Ziqubu, K., Nkambule, B.B., Mazibuko-Mbeje, S.E., Hanser, S., Basson, A.K., Pheiffer, C., Kengne, A.P.: Pancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress. World J. Diabetes. 14, 130–146 (2023). https://doi.org/10.4239/wjd.v14.i3.130
29. Wysham, C., Shubrook, J.: Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications. Postgrad. Med. 132, 676–686 (2020). https://doi.org/10.1080/00325481.2020.1771047
30. Chang, W., Meng, Z., Zhao, Y., Qi, Y., Li, Z., Lian, H.: Emerging Nanotechnology Strategies for Obesity Therapy. Adv. Sci. 12, e01813 (2025). https://doi.org/10.1002/advs.202501813
31. Mohite, P., Singh, S., Pawar, A., Sangale, A., Prajapati, B.G.: Lipid-based oral formulation in capsules to improve the delivery of poorly water-soluble drugs. Front. Drug Deliv. 3, (2023). https://doi.org/10.3389/fddev.2023.1232012
32. Elieh Ali Komi, D., Shafaghat, F., Christian, M.: Crosstalk Between Mast Cells and Adipocytes in Physiologic and Pathologic Conditions. Clin. Rev. Allergy Immunol. 58, 388–400 (2020). https://doi.org/10.1007/s12016-020-08785-7
33. Zhang, Q., Lu, C., Lu, F., Liao, Y., Cai, J., Gao, J.: Challenges and opportunities in obesity: the role of adipocytes during tissue fibrosis. Front. Endocrinol. 15, (2024). https://doi.org/10.3389/fendo.2024.1365156
34. Eltaib, L.: Polymeric Nanoparticles in Targeted Drug Delivery: Unveiling the Impact of Polymer Characterization and Fabrication. Polymers. 17, (2025). https://doi.org/10.3390/polym17070833
35. Wang, Y., Li, H., Rasool, A., Wang, H., Manzoor, R., Zhang, G.: Polymeric nanoparticles (PNPs) for oral delivery of insulin. J. Nanobiotechnology. 22, 1 (2024). https://doi.org/10.1186/s12951-023-02253-y

36. Zielińska, A., Carreiró, F., Oliveira, A.M., Neves, A., Pires, B., Venkatesh, D.N., Durazzo, A., Lucarini, M., Eder, P., Silva, A.M., Santini, A., Souto, E.B.: Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology. Molecules. 25, 3731 (2020). https://doi.org/10.3390/molecules25163731
37. Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., Cai, L.: Smart nanoparticles for cancer therapy. Signal Transduct. Target. Ther. 8, 418 (2023). https://doi.org/10.1038/s41392-023-01642-x
38. Nunziata, G., Pollonio, D., Lacroce, E., Rossi, F.: Smart pH-Responsive polymers in biomedical Applications: Nanoparticles, hydrogels, and emerging hybrid platforms. Mater. Today Chem. 49, 103063 (2025). https://doi.org/10.1016/j.mtchem.2025.103063
39. Yang, H.-Y., Wei, Y., Mao, Q., Zhao, L.-H.: Immune activation induced by dysregulated lipid metabolism in the pathogenesis of type 2 diabetes. World J. Diabetes. 16, 114395 (2025). https://doi.org/10.4239/wjd.v16.i12.114395
40. Alghamdi, M.A., Fallica, A.N., Virzì, N., Kesharwani, P., Pittalà, V., Greish, K.: The Promise of Nanotechnology in Personalized Medicine. J. Pers. Med. 12, 673 (2022). https://doi.org/10.3390/jpm12050673
41. Azmi, N.A.N., Elgharbawy, A.A.M.: Advances in Medical Applications: The Quest of Green Nanomaterials. In: Shanker, U., Hussain, C.M., and Rani, M. (eds.) Handbook of Green and Sustainable Nanotechnology: Fundamentals, Developments and Applications. pp. 1889–1909. Springer International Publishing, Cham (2023)
42. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., De Campos, O.C., Udeozor, P.A., Nfona, S.O., Lawal, B., Alum, E.U.: Modulation of Lipogenesis by Tetracarpidium conophorum Nuts via SREBP-1/ACCA-1/FASN Inhibition in Monosodium-Glutamate-Induced Obesity in Rats. Nat. Prod. Commun. 20, 1934578X251344035 (2025). https://doi.org/10.1177/1934578X251344035
43. Padmanaban, S., Pully, D., Samrot, A.V., Gosu, V., Sadasivam, N., Park, I.-K., Radhakrishnan, K., Kim, D.-K.: Rising Influence of Nanotechnology in Addressing Oxidative Stress-Related Liver Disorders. Antioxidants. 12, (2023). https://doi.org/10.3390/antiox12071405
44. Vishvanath, L., Gupta, R.K.: Contribution of adipogenesis to healthy adipose tissue expansion in obesity. J. Clin. Invest. 129, 4022–4031. https://doi.org/10.1172/JCI129191
45. Jouy, S.H., Mohan, S., Scichilone, G., Mostafa, A., Mahmoud, A.M.: Adipokines in the Crosstalk between Adipose Tissues and Other Organs: Implications in Cardiometabolic Diseases. Biomedicines. 12, (2024). https://doi.org/10.3390/biomedicines12092129
46. Zhou, C., Gui, W., Zhu, W., Zhao, H., Wu, D., Wu, F., Wang, G., Lin, X.: Paradoxical regulation of IGF2 in promoting lipid metabolism in adipose tissues. Commun. Biol. 8, 1026 (2025). https://doi.org/10.1038/s42003-025-08458-1
47. Janjua, T.I., Cao, Y., Kleitz, F., Linden, M., Yu, C., Popat, A.: Silica nanoparticles: A review of their safety and current strategies to overcome biological barriers. Adv. Drug Deliv. Rev. 203, 115115 (2023). https://doi.org/10.1016/j.addr.2023.115115
48. Onaciu, A., Jurj, A., Moldovan, C., Berindan-Neagoe, I., Onaciu, A., Jurj, A., Moldovan, C., Berindan-Neagoe, I.: Theranostic Nanoparticles and Their Spectrum in Cancer. In: Engineered Nanomaterials - Health and Safety. IntechOpen (2019)
49. Jin, X., Qiu, T., Li, L., Yu, R., Chen, X., Li, C., Proud, C.G., Jiang, T.: Pathophysiology of obesity and its associated diseases. Acta Pharm. Sin. B. 13, 2403–2424 (2023). https://doi.org/10.1016/j.apsb.2023.01.012
50. Đorđević, S., Gonzalez, M.M., Conejos-Sánchez, I., Carreira, B., Pozzi, S., Acúrcio, R.C., Satchi-Fainaro, R., Florindo, H.F., Vicent, M.J.: Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv. Transl. Res. 12, 500–525 (2022). https://doi.org/10.1007/s13346-021-01024-2
51. De Jong, W.H., Geertsma, R.E., Borchard, G.: Regulatory safety evaluation of nanomedical products: key issues to refine. Drug Deliv. Transl. Res. 12, 2042–2047 (2022). https://doi.org/10.1007/s13346-022-01208-4

CITE AS: Mercy Latricia (2026). Nanotechnology-Based Interventions for Obesity-Associated Insulin Resistance and Diabetes Progression. IDOSR JOURNAL OF SCIENTIFIC RESEARCH 11(2):90-95. https://doi.org/10.59298/IDOSRJSR/2026/11.2.9095